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Viral hepatitis A, B and C are contagious 
liver diseases that cause major public 
health problems worldwide. For hepati-
tis B and hepatitis C in particular, acute 
infection may progress to chronic dis-
ease, which can lead to cirrhosis of the liv-
er and hepatocellular carcinoma. Hepati-
tis  A virus causes only acute infections, 
but a fulminant course of infection with 
liver failure may rarely occur. The mor-
tality of acute hepatitis A in people old-
er than 60 years is 2%. According to the 
German Protection against Infection Act 
(“Infektionsschutzgesetz”, IfSG), all sus-
pected, diagnosed or deceased cases of 
viral hepatitis and all laboratory-con-
firmed cases of acute viral hepatitis (in 
case of hepatitis C: all newly diagnosed 
infections) in Germany must be notified 
to the local public health departments. 
Anonymised case reports are forward-
ed to the state public health departments 
in charge and electronically transmitted 
to the Robert Koch Institute (RKI). As-
sessment of hepatitis prevalence in the 
population based solely on data report-
ed in accordance with the IfSG are sub-
ject to a range of limitations, as only new-
ly diagnosed and acute infections are re-
ported. In many cases viral hepatitis pro-
gresses without clinical symptoms and is 
not diagnosed in an early stage. Further-
more, information on immunity acquired 
through vaccination is not available from 
the national case reports. Therefore the 
information on the overall immunity of 
the population is incomplete. In order 
to develop targeted prevention strategies 
and to adapt vaccination recommenda-
tions, representative seroepidemiological 
surveillance is required. Ten years after 
the first seroepidemiological survey, the 
German National Health Interview and 
Examination Survey 1998 (GNHIES98), 
current and extensive data for hepati-
tis A, B and C are now available from the 
German Health Interview and Examina-
tion Survey for Adults (“Studie zur Ge-
sundheit Erwachsener in Deutschland”, 
DEGS).
Methods
The German Health Interview and Ex-
amination Survey for Adults (DEGS) is 
part of the health monitoring system at 
the Robert Koch Institute (RKI). The 
concept and design of DEGS are de-
scribed in detail elsewhere [1, 2, 3, 4, 5]. 
The first wave (DEGS1) was conduct-
ed from 2008–2011 and comprised in-
terviews, examinations and tests [6, 7]. 
The target population comprises the res-
ident population of Germany aged 18–
79 years. DEGS1 has a mixed study de-
sign, which permits both cross-sectional 
and longitudinal analyses. For this pur-
pose, a random sample from local pop-
ulation registries was drawn to com-
plete the participants of the German Na-
tional Health Interview and Examina-
tion Survey 1998 (GNHIES98). A total 
of 8,152 persons participated, including 
4,193 first-time participants (response 
rate 42%) and 3,959 revisiting partici-
pants of GNHIES98 (response rate 62%). 
There were 7,238 persons who attend-
ed one of the 180 examination centres, 
and 914 were only interviewed. The net 
sample (n=7,988) permits representative 
cross-sectional and trend analyses for the 
age range of 18–79 years in comparison 
with GNHIES98 (n=7,124) [2]. The data 
of the revisiting participants can be used 
for longitudinal analyses. The cross-sec-
tional and trend analyses are conducted 
using a weighting factor, which corrects 
deviations in the sample from the popu-
lation structure (as of 31 Dec 2010) with 
respect to age, sex, region and national-
ity as well as community type and edu-
cation [2]. A separate weighting factor 
was generated for the examination part 
of the study. Calculation of the weight-
ing factor also considered re-participa-
tion probability of GNHIES98 partici-
pants based on a logistic regression mod-
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el. For the purpose of conducting trend 
analyses, the data from the GNHIES98 
were age-adjusted to the population level 
as of 31 Dec 2010. A non-response analy-
sis and a comparison of selected indica-
tors with data from census statistics in-
dicate a high level of representativeness 
of the net sample for the resident popu-
lation aged 18–79 years in Germany [2]. 
To take into account both the weighting 
as well as the correlation of participants 
within a municipality, the confidence in-
tervals were determined using SPSS 20 
procedures for complex samples. Differ-
ences are considered statistically signifi-
cant if the respective 95% confidence in-
tervals do not overlap.
Social status was determined using 
an index, which includes information on 
school education and vocational training, 
professional status and net household in-
come (weighted by household needs) per-
mitting classification into low, middle and 
high status groups [8].
To assess the prevalence of seromark-
ers for hepatitis A, B and C, serum sam-
ples from 7,047 (7,046 for hepatitis A) of 
the 7,116 persons included in the cross-
sectional survey were analysed (99%). Da-
ta from the current survey were compared 
with the results of GNHIES98.
Hepatitis A
Immunoglobulin G (IgG) antibodies 
against hepatitis A virus (anti-HAV) were 
qualitatively detected with the HAV che-
miluminescence microparticle immuno-
assay (CMIA) on an ARCHITECT de-
vice (here and below: Abbott Diagnos-
tics). Samples with an S/CO (sample/cut 
off) below 1.0 were considered not reac-
tive, i.e. not detectable, and samples with 
an S/CO ≥1.0 were considered reactive, 
i.e. positive.
Hepatitis B
Each sample was first tested for antibod-
ies against hepatitis B core (anti-HBc) and 
surface antigen (anti-HBs). Testing for an-
ti-HBc was done qualitatively using the 
CMIA on an ARCHITECT device. Sam-
ples with an S/CO below 1.0 were consid-
ered not reactive, i.e. not detectable, and 
samples with an S/CO≥1.0 were consid-
ered reactive, i.e. positive.
Anti-HBs levels were determined 
quantitatively using the CMIA on an AR-
CHITECT device. In accordance with the 
criteria of the ARCHITECT anti-HBs as-
say, samples with an anti-HBs concentra-
tion of less than 10.0 mIU/ml were consid-
ered not reactive, i.e. not detectable, and 
samples with an anti-HBs concentration 
≥10 mIU/ml were considered reactive, i.e. 
positive.
Test results reactive for Anti-HBc and 
non-reactive for anti-HBs (<10 mIU/ml) 
were re-tested with an independent anti-
HBc test and for the presence of HBsAg. 
In accordance with the criteria of the AR-
CHITECT HBsAg assay, samples with a 
concentration <0.05 IU/ml were consid-
ered not reactive, and samples ≥0.05 IU/
ml were considered initially reactive and 
were then tested again. Only if this addi-
tional test was reactive, the sample was 
considered positive. In samples tested 
anti-HBc positive and anti-HBs positive, 
the respective subjects were considered 
to have been exposed to hepatitis B virus 
with acquisition of immunity. These are 
persons who have had a hepatitis B in-
fection and recovered from it. Anti-HBc 
positive and HBsAg positive participants 
were classified as suffering from hepati-
tis B (active acute or chronic hepatitis B 
infection). Subjects who tested positive 
for anti-HBc only generally can be as-
sumed to have a history of resolved hep-
atitis B infection (with or without im-
munity). The presence of anti-HBc on-
ly can be explained by a waning of an-
ti-HBs antibodies after a previous infec-
tion, by an occult chronic infection with-
out measureable HBsAg or by false posi-
tive reactions [9]. A positive anti-HBs re-
sult (≥10.0 mIU/ml) without presence of 
other markers is interpreted as immuni-
ty acquired through vaccination.
Hepatitis C
Antibodies against hepatitis C virus (an-
ti-HCV) were detected qualitatively us-
ing the anti-HCV CMIA on an ARCHI-
TECT device. Samples with an S/CO be-
low 1.0 were considered not reactive, i.e. 
not detectable, samples with an S/CO 
≥1.0 were considered reactive, i.e. posi-
tive, in accordance with ARCHITECT 
anti-HCV assay criteria. Samples show-
ing the same result in a second testing, 
were considered positive for anti-HCV 
and were then tested for the presence of 
HCV RNA by polymerase chain reaction 
(PCR). HCV RNA positive samples were 
classified as “active hepatitis C infection”. 
If no viral RNA was found, the antibody 
test result was confirmed by immunob-
lot. An immunoblot-confirmed positive 
antibody-test without evidence of vi-
ral RNA was classified as cleared hepati-
tis C virus infection. RNA- positive and 
immunoblot-confirmed samples were 
summed up to calculate the overall prev-
alence of hepatitis C.
Initially, PCR was performed using 
the Cobas AmpliPrep/Cobas TaqMan 
Test (limit of detection 15 IU/ml) un-
til September 2010, from then until Oc-
tober 2011 using the VERSANT HCV 
RNA qualitative TMA assay (limit of 
detection 10 IU/ml). Quantitative HCV 
RNA determination was performed with 
Tab. 1 Prevalence of antibodies against the hepatitis A virus (anti-HAV) by sex and age group from DEGS1 2008–2011 as percentages with 95% 
confidence intervals. nunweighted=7,046
Age group 18–19 years 20–29 years 30–39 years 40–49 years 50–59 years 60–69 years 70–79 years Overall
Sex


















































the VERSANT HCV RNA 3.0 bDNA as-
say and from October 2011 onwards us-
ing the VERSANT HCVB RNA 1.0 kP-
CR assay (limit of detection 15 IU/ml) by 
Siemens Healthcare Diagnostics (Esch-
born). The immunoblot was carried out 
using the Chiron Riba HCV 3.0 test un-
til September 2010, using the recomBlot 
HCV IgG 2.0 test until October 2011, and 
using the recomLine HCV IgG test there-




The average prevalence of antibodies 
against hepatitis A virus (anti-HAV) is 
48.6% among adults aged 18–79 years and 
does not differ significantly between men 
and women. There are considerable dif-
ferences between age groups. The preva-
lence of anti-HAV increases overall with 
age and for 70–79 year olds it exceeds 
80%. Notable, however, are the relatively 
constant seroprevalences of around 40% 
for the age groups from 20–59 years. For 
the age group 30–49 years there is no in-
crease in seroprevalence as compared to 
the next youngest age group. The larg-
est rise in the prevalence of antibodies 
between consecutive age groups is on-
ly observed between the age groups 50–
59 years and 60–69 years. This pattern is 
particularly evident among women aged 
40–49 years. The antibody prevalence of 
34.0% (95% confidence interval 29.3–
39.1) in this age group is even statistically 
significantly lower than that in the next 
younger age group (. Tab. 1).
A multivariate logistic regression mod-
el adjusted for age and sex shows an as-
sociation between the prevalence of an-
ti-HAV and socioeconomic status (SES). 
The anti-HAV prevalence among adults 
with low or high SES is higher than among 
adults with middle SES (low versus mid-
dle SES odds ratio (OR) 1.22 (1.02–1.46), 
high versus middle SES OR 1.28 (1.08–
1.52)).
Overall, the anti-HAV seropreva-
lence among men and women aged 18–
79 is very similar to the figure obtained 
10 years ago in GNHIES98 (. Tab. 2). 
However, in GNHIES98 the seroprev-
alence rose continuously across all age 
groups, with a particularly large increase 
from age group 30–39 years to age group 
40–49 years (. Tab. 2). When consid-
ering the anti-HAV seroprevalence fig-
ures stratified by age, the current da-
ta from DEGS1 shows higher preva-
lence figures for the younger age groups 
from 18–39 years. In contrast, the sero-
prevalence figures for the age groups 
from 50–79 years are considerably lower 
than those obtained 10 years ago in GN-
HIES98 (. Fig. 1).
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Abstract
Ten years after seroepidemiological data 
were obtained in the German National Health 
Interview and Examination Survey 1998 (GN-
HIES98), German Health Interview and Ex-
amination Survey (DEGS1) data contribute to 
a population-based, representative surveil-
lance of hepatitis A and B immunity and of 
the serological markers for hepatitis C in Ger-
many. The prevalence of antibodies against 
the hepatitis A virus is 48.6%. In comparison 
to the situation 10 years ago, seroprevalence 
is significantly higher among 18- to 39-year-
old adults and is significantly lower in those 
aged 50–79 years. The association between 
age and seroprevalence has changed, indi-
cating a decrease in naturally acquired hep-
atitis A immunity. Individual and population 
immunity has to be achieved through vacci-
nation. Prevalence of hepatitis B antibodies 
indicates that 5.1% of adults have been ex-
posed to the virus, significantly fewer than 
10 years ago (7.9%). Prevalence of hepati-
tis B surface antibodies indicates that 22.9% 
of adults have been vaccinated against hep-
atitis B. Vaccination coverage has increased 
in all age groups and is highest in the young-
er age groups. These positive trends can be 
attributed to the general recommendation 
since 1995 to vaccinate against hepatitis B. 
For hepatitis C, the prevalence of antibodies 
in the general population is 0.3%. Germany 
thus remains a low-HCV-endemic country.
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Die Seroepidemiologie der Hepatitis A, B und C in Deutschland. 
Ergebnisse der Studie zur Gesundheit Erwachsener 
in Deutschland (DEGS1)
Zusammenfassung
Die Daten aus der Studie zur Gesundheit Er-
wachsener in Deutschland (DEGS1) ermögli-
chen 10 Jahre nach der seroepidemiologi-
schen Erhebung im „Bundes-Gesundheitssur-
vey 1998“ (BGS98) die Abschätzung der ak-
tuellen Durchseuchung mit Hepatitis-A-, He-
patitis-B- und Hepatitis-C-Viren und der Im-
munitätslage gegen Hepatitis A und B sow-
ie diesbezüglicher zeitlicher Trends in der 
Be völkerung. Die Seroprävalenz von Anti-
körpern gegen das Hepatitis-A-Virus be-
trägt 48,6%. Im Vergleich zu den Werten vor 
10 Jahren liegt sie bei den 18- bis 39-Jährigen 
signifikant höher, bei den 50- bis 79-Jähri-
gen dagegen signifikant niedriger. Das verän-
derte Muster in der altersabhängigen Sero-
prävalenz zeigt einen Rückgang der natürli-
chen Durchseuchung mit dem Hepatitis-A-
Virus. Ein individueller Schutz vor Hepati-
tis A und eine gute Immunität auf Bevölke-
rungsebene sind daher nur durch Schutzimp-
fungen zu erreichen. 5,1% der Erwachsenen 
weisen Marker für eine Hepatitis-B-Virus-In-
fektion auf; dieser Wert ist signifikant nied-
riger als vor 10 Jahren. Bei 22,9% der Frauen 
und Männer kann auf eine durch Impfung 
hervorgerufene Immunität gegen Hepatitis B 
geschlossen werden. Dieser Anteil sinkt mit 
dem Alter, ist aber über alle Altersgruppen 
hinweg signifikant gestiegen. Es zeigen sich 
bereits deutliche Erfolge der seit 1995 allge-
mein empfohlenen Hepatitis-B-Impfung. Die 
Durchseuchung mit Hepatitis-C-Viren liegt 
bei 0,3%; damit gehört Deutschland weiter-
hin zu den Ländern mit einer diesbezüglich 
niedrigen Prävalenz.
Schlüsselwörter
Gesundheitssurvey · Hepatitis A · Hepatitis B · 
Hepatitis C · Seroepidemiologie
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Tab. 3 Prevalence of hepatitis B and hepatitis C seromarkers by sex and age group from DEGS1 2008–2011 as percentages with 95% confi-
dence intervals. nunweighted =7,047
Age group 18–19 years 20–29 years 30–39 years 40–49 years 50–59 years 60–69 years 70–79 years Overall
Hepatitis B
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Anti-HBc and HBs-Ag 
positivea
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aacute or chronic infection; bhealed infection; cprevious infection, immunity questionable; dimmunity through vaccination.
Tab. 2 Prevalence of antibodies against the hepatitis A virus (anti-HAV) by sex and age group from GNHIES98 as percentages with 95% confi-
dence intervals (age-standardised for state of population as of 31 Dec 2010). nunweighted =6,748
Age group 18–19 years 20–29 years 30–39 years 40–49 years 50–59 years 60–69 years 70–79 years Overall
Sex




















































The results of for hepatitis B seromarkers 
are listed in . Tab. 3. A total of 5.1% of 
adults were positive for antibodies against 
hepatitis B core antigen (anti-HBc) and 
thus markers for hepatitis B infection 
(women 4.8% (4.0–5.8), men 5.3% (4.3–
6.5)). The prevalence of acute or chron-
ic HBV infection (anti-HBc positive and 
HBsAg positive) is 0.3%. The relatively 
high prevalence among men (0.5%; 0.2–
1.1) as compared to women (0.2%; 0.1–0.4) 
is statistically not significant. Age-strati-
fied analyses were not performed due to 
low case numbers. The prevalence of an-
ti-HBc/anti-HBs positive samples as se-
rological evidence for resolved hepati-
tis B infection is 4.1% and is higher for the 
elder age groups as compared to young-
er ones. It does not differ between wom-
en and men. The prevalence of anti-HBc 
only in the study population is 0.6%. This 
serological result, classified as exposure 
to HBV without evidence of acquired im-
munity, was slightly more frequent in men 
than in women, but without statistical dif-
ference. A multivariate logistic regression 
model adjusted for age and sex shows a 
correlation between hepatitis B infection 
and socioeconomic status (SES) (low ver-
sus high SES: OR 3.82 (2.57–5.66), mid-
dle versus high SES: OR 1.76 (1.20–2.58)). 
The lower the social status, the higher is 
the risk of hepatitis B infection.
A total of 22.9% of participants tested 
positive for anti-HBs exclusively, indicat-
ing a vaccination-acquired HBV-immu-
nity. Immunity due to vaccination differs 
significantly between women and men, 
with women having a considerably higher 
anti-HBs-seroprevalence. Although the 
differences in individual age groups are 
not statistically significant, the preva-
lence of anti-HBs is clearly higher among 
younger women below 30 years of age as 
compared to men in the same age-group: 
Among 18- to 19-year-old persons, wom-
en had a prevalence of anti-HBs of 70.9% 
compared to 61.6% in men, and in 20- to 
29-year-old persons, anti-HBs prevalence 
in women was 62.1% compared to 51.8% 
in men. A multivariate logistic regression 
model adjusted for age and sex shows an 
association between vaccination-acquired 
immunity against HBV and SES (high 
versus low SES: OR 3.53 (2.62–4.76), mid-
dle versus low SES: OR 2.08 (1.60–2.69)). 
Low SES thus is associated with the lack 
of vaccination-acquired immunity. The 
risk of HBV infection (current infection 
or history of infection) is higher for adults 
with low SES than for persons with mid-
dle SES, and it is also higher for persons 
with middle SES as compared to those 
with high SES.
The proportion of exclusively anti-
HBs positive samples for men and wom-
en across all age groups is considerably 
higher in the current survey (. Fig. 2) as 
compared to the results from GNHIES98 
(. Tab. 4). This increase in the propor-
tion of vaccinated subjects is greatest for 
the age group 18–29 years. The overall 
proportion of anti-HBc positive adults as 
marker for HBV infection is 5.1% (4.4–
5.8) significantly lower than 10 years ago 
(7.9% (6.9–9.1)). Prevalence figures from 
GNHIES98, age-adjusted for the current 
population structure (. Tab. 4), indicate 
an even more important decrease of HBV 
infection in the German population from 
8.7% (7.7–9.9) to 5.1% (4.4–5.8). This dif-
ference is most distinct in the oldest age 
group of 70–79 years.
Hepatitis C
The average prevalence of antibodies 
against the hepatitis C virus (anti-HCV) 
among the study population is 0.3%. Ev-
idence of HCV RNA was found in two 
thirds of HCV positive samples (overall 
0.2%). In one third (overall 0.1%) antibod-
ies against HCV were present, but no viral 
RNA was detected. Thus markers for in-
fection with HCV are present in a total of 
0.3% (0.1–0.5) of adults (. Tab. 3). Mul-
tivariate logistic regression did not reveal 












18-19 years 20-29 years 30-39 years 40-49 years 50-59 years 60-69 years 70-79 years
DEGS: solely Anti-HBs positive (vaccinated)
BGS: solely Anti-HBs positive (vaccinated)BGS: Anti-HBc total
DEGS: Anti-HBc total
Fig. 2 8 Prevalence of hepatitis B seromarkers as percentages by age group in DEGS1 and in 












18-19 years 20-29 years 30-39 years 40-49 years 50-59 years 60-69 years 70-79 years
DEGS Anti-HAV positiveBGS98 Anti-HAV positive
Fig. 1 8 Seroprevalence of antibodies against the hepatitis A virus as percentages by age group in 
DEGS1 and in GNHIES98 (weighted for state of population as of 31 Dec 2010), n=7,046
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(data not shown). Anti-HCV-positive re-
sults were found exclusively in age groups 
40–79 years.
Overall HCV prevalence in the cur-
rent survey does not differ from results 
obtained 10 years ago in GNHIES98 (con-
firmed anti-HCV 0.4%, (0.2–0.6)). How-
ever, in contrast to GNHIES98, where 
20- to 29-year-old persons and older in-
dividuals tested positive for anti-HCV, 
in DEGS1 no persons below the age of 




Hepatitis A is an acute inflammation of 
the liver, whose symptoms typically in-
clude jaundice and which typically is of 
relatively short duration and complete-
ly resolves. However, mortality increases 
with age (approx. 2% among over 60 year 
olds). The hepatitis A virus is excreted 
with the faeces and is transmitted from 
person to person and via contaminated 
food. In countries with low standards of 
hygiene the incidence of infection is very 
high already among children. In Europe 
and North America the incidence has de-
clined steadily over the last 10 years, so 
that ever fewer adolescents and adults 
have naturally acquired immunity to the 
hepatitis A virus. Vaccination is available 
in Germany and since 1993 has been rec-
ommended by the Standing Commit-
tee for Vaccination (“Ständige Impfkom-
mission”, STIKO) for travellers to regions 
with a high prevalence of hepatitis A and 
for persons with increased risk of infec-
tion due to occupational exposure or sex-
ual behaviour [10].
Almost 50% of adult men and wom-
en in Germany have antibodies against the 
hepatitis A virus. These were acquired ei-
ther naturally (previous infection) or as 
a result of hepatitis A vaccination. Anti-
bodies against the hepatitis A virus are 
found in a smaller proportion in adults 
with middle SES than in adults with low 
or high SES. Taking into account the low 
hepatitis A vaccination rates for adults 
with low SES and the high vaccination 
rates for adults with high SES shown in 
another publication in this issue [11], this 
result indicates that immunity was more 
often acquired naturally among people 
with low SES and more often via vaccina-
tion among people with high SES.
The overall prevalence of anti-HAV 
does not differ from the data gathered 
in the years from 1997–1999 [12]. In both 
surveys the overall seroprevalence con-
siderably increases by age. However, the 
current DEGS1 pattern of age-dependen-
cy clearly differs from the steady rise of 
anti-HAV seroprevalence with age in 
the GNHIES98. Currently the seroprev-
Tab. 4 Prevalence of hepatitis B seromarkers by sex and age group from GNHIES98 as percentages with 95% confidence intervals (age-stan-
dardised for state of population as of 31 Dec 2010). nunweighted =6,747
Age group 18–19 years 20- 29 years 30–39 years 40–49 years 50–59 years 60–69 years 70–79 years Overall
Sex
Women
Anti-HBc and HBs 
antigen positivea
0 0 0 0.6 (0.2–2.4) 0.3 (0.0–2.2) 0.6 (0.2–2.4) 0.8 (0.1–5.7) 0.4 (0.2–0.9)
Anti-HBc and 
anti-HBs positiveb
1.6 (0.2–10.7) 3.3 (1.5–7.2) 3.6 (2.2–5.9) 6.7 (4.5–9.8) 5.5 (3.6–8.5) 9.9 (7.2–13.4) 13.6 (9.5–19.1) 6.7 (5.6–8.1)
Only anti-HBc 
positivec
0 1.8 (0.6–5.5) 0.5 (0.1–3.8) 0.5 (0.2–1.7) 0.2 (0.0–1.2) 0.7 (0.2–2.2) 1.2 (0.4–3.6) 0.8 (0.4–1.4)
Only anti-HBs 
positived
13.2 (7.5–22.2) 12.3 (9.3–16.1) 9.6 (7.5–12.1) 6.0 (4.4–8.2) 4.4 (2.7–7.2) 1.0 (0.3–2.7) 0.4 (0.1–1.8) 5.9 (5.0–7.0)
Men
Anti-HBc and HBs 
antigen positivea
0.9 (0.1–6.3) 0.4 (0.1–2.0) 2.1 (0.9–4.6) 1.4 (0.6–3.2) 2.0 (0.9–4.3) 0.5 (0.1–2.5) 0.3 (0.0–2.2) 1.2 (0.8–2.0)
Anti-HBc and 
anti-HBs positiveb
1.1 (0.2–4.9) 4.3 (2.4–7.7) 3.0 (1.8–5.0) 6.5 (4.4–9.4) 7.6 (5.4–10.5) 5.6 (3.7–8.3) 15.5 (10.7–21.9) 6.5 (5.4–7.8)
Only anti-HBc 
positivec
0 0.6 (0.1–4.0) 1.3 (0.5–3.4) 0.8 (0.3–2.0) 2.8 (1.5–5.3) 2.3 (0.9–5.6) 3.6 (1.5–8.3) 1.7 (1.1–2.5)
Only anti-HBs 
positived
5.3 (2.5–10.9) 4.9 (3.1–7.9) 5.1 (3.5–7.4) 3.1 (2.0–4.9) 1.1 (0.4–2.6) 0.5 (0.2–1.8) 0 2.7 (2.2–3.4)
Overall
Anti-HBc and HBs 
antigen positivea
0.5 (0.1–3.3) 0.2 (0.0–1.0) 1.1 (0.5–2.4) 1.0 (0.5–2.0) 1.2 (0.6–2.4) 0.5 (0.2–1.6) 0.6 (0.1–2.8) 0.8 (0.5–1.2)
Anti-HBc and 
anti-HBs positiveb
1.4 (0.4–4.8) 3.8 (2.4–6.0) 3.3 (2.3–4.7) 6.6 (4.9–8.8) 6.5 (4.9–8.7) 7.8 (6.0–10.0) 14.5 (11.0–18.8) 6.6 (5.7–7.6)
Only anti-HBc 
positivec
0 1.2 (0.5–3.1) 0.9 (0.4–2.3) 0.6 (0.3–1.3) 1.5 (0.8–2.8) 1.5 (0.7–3.1) 2.3 (1.2–4.5) 1.2 (0.9–1.7)
Only anti-HBs 
positived
9.2 (5.6–14.7) 8.6 (6.9–10.7) 7.3 (5.9–9.0) 4.6 (3.5–6.0) 2.8 (1.8–4.2) 0.8 (0.3–1.6) 0.2 (0.1–1.0) 4.3 (3.8–5.0)




alence figures for anti-HAV in the age 
groups from 18–39 years are higher than 
10 years ago, while in the groups from 50–
79 years, on the other hand, they are low-
er. This means that the proportion of old-
er men and women with no immunity 
to the hepatitis A virus has risen sharply 
over the last 10 years. Taking into consid-
eration the continuous decrease of hepati-
tis A incidence across all age groups based 
on the case notifications according to the 
German Protection against Infection Law 
(IfSG) [13], the considerably higher an-
ti-HAV seroprevalence in age groups 
18–39 years are most likely due to an in-
creased hepatitis A vaccination coverage 
(for example before travelling abroad). 
While well over 2,000 cases of hepatitis A 
infection were notified in 2001 (2,271 in 
2001), since 2009 there have been fewer 
than 1,000 annually notified cases. The 
DEGS1 results are also consistent with the 
data based on IfSG notifications regard-
ing distribution by sex, i.e. anti-HAV sero-
prevalence is not different between males 
and females.
Two large, representative seroepide-
miological surveys were carried out in the 
Netherlands from 1995 to 1996 and over 
2006/2007 on the anti-HAV prevalence. 
They found an increase in the prevalence 
of anti-HAV from 34 to 39.3%, which was 
attributed to increasing vaccination cov-
erage and a higher proportion of immi-
grants [14]. Anti-HAV prevalence in the 
Netherlands is thus lower than the prev-
alence observed in Germany. However, it 
is also highly age-dependent. In the Dutch 
surveys also conducted at 10-year inter-
vals, an increase in the proportion of old-
er men and women who are not immune 
to the hepatitis A virus is also evident.
Conclusion
The data available from DEGS1 on the se-
roprevalence of anti-HAV provides an up-
to-date, population-based and valid esti-
mate of immunity to the hepatitis A vi-
rus. Anti-HAV antibodies indicating pro-
tection against hepatitis A can be detected 
for a long time after vaccination [15] and 
even longer after previous infection [16, 
17]. Currently younger age groups are bet-
ter protected, while older age groups are 
less protected against infection with the 
hepatitis A virus than 10 years ago. Better 
hygienic conditions have led to a reduc-
tion in the incidence of HAV infection. 
Individual protection against the hepati-
tis A virus and good immunity at a popu-
lation level can therefore only be achieved 
in Germany by vaccination. Generally it is 
important to ensure that the vaccination 
recommendations made by the STIKO are 
properly implemented in practice. This 
is particularly important for older peo-
ple travelling to high-prevalence regions, 
since hepatitis A can be particularly severe 
in these age groups and prevalence of nat-
ural immunity is decreasing.
Hepatitis B
Hepatitis B is a contagious liver inflamma-
tion of worldwide significance, caused by 
HBV and is transmitted primarily sexually 
or via blood. Among adults the infection 
usually resolves, but in up to 10% of cases, 
the virus can cause chronic liver infection 
that can later develop into cirrhosis of the 
liver and hepatocellular carcinoma. Since 
1982 (West Germany) and 1984 (East Ger-
many) vaccination has been recommend-
ed for groups with increased risk of infec-
tion. In 1995, the general recommendation 
for HBV-vaccination of all neonates and 
non-vaccinated older children and ado-
lescents was implemented by the Scientif-
ic Secretariat of the Standing Committee 
on Vaccination at the Robert Koch Insti-
tute (STIKO) [18].
The overall prevalence of infection 
with hepatitis B virus is 5.1% and does not 
differ between men and women. The se-
rological findings most frequently indi-
cate previous hepatitis B infection with 
acquired immunity. However, compared 
with the seroprevalence figures obtained 
in GNHIES98 10 years ago the DEGS da-
ta indicate a decrease in HBV infection. 
This positive development is most clearly 
seen in the young age groups. At the same 
time, the proportion of persons who have 
been vaccinated has increased consider-
ably, particularly in the young age groups. 
It can therefore be assumed that the gen-
eral vaccination for children recommend-
ed by the STIKO is already showing an 
impact. A positive trend is also evident in 
the prevalence of current acute or chronic 
HBV infection. The HBsAg prevalence of 
0.8% measured in GNHIES98 10 years ago 
has decreased to 0.3%. The positive trend 
observed in the seroprevalence figures 
can also be seen in the national surveil-
lance data for HBV. Reported case num-
bers of acute HBV infection are steadily 
decreasing and stable since the year 2007. 
The decrease is particularly pronounced 
among young age groups. However, a sim-
ilar reduction is also evident among old-
er age groups, indicating that, in addition 
to the success of HBV vaccination, gener-
al prevention measures (for example hy-
giene regulations in healthcare, improved 
safety of blood and blood products) seem 
to be having an effect. The annual inci-
dence figures of hepatitis B (IfSG), how-
ever, continue to show a distinct differ-
ence between men and women (in 2010, 
0.6 cases per 100,000 women, 1.3 cases 
per 100,000 men). Starting from the age 
group 25–29 years there was a consistently 
higher incidence among men than among 
women of the same age [19]. In contrast, 
the seroprevalence figures from DEGS1 
show virtually no difference between men 
and women with respect to the seromark-
ers indicating acute or previous hepati-
tis B infection. This discrepancy can be 
explained by the fact that the higher inci-
dence of hepatitis B among men is proba-
bly attributable to high-risk sexual behav-
iour and to more frequent intravenous 
drug use among men. The true prevalence 
tends to be underestimated in population-
based surveys.
Fifteen years after the introduction of 
the general hepatitis B vaccination, trends 
appear to be positive given the decrease 
in the total percentage of persons infect-
ed with hepatitis B and in the incidence 
of hepatitis B in particular among young 
adults and children in Germany. Similar 
trends have also been described in Italy, 
where vaccination was generally recom-
mended in 1991 [20].
Conclusion
The seroprevalence figures obtained in 
DEGS1 give a measure of the situation re-
garding HBV infection and immunity in 
the population at large. Today, particu-
larly the younger age groups are consid-
erably better protected against hepatitis B 
than 10 years ago. Overall, lifetime prev-
alence of HBV infection has decreased. 
The risk of infection decreases with high-
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er social status. On the one hand the ob-
served reduction in overall prevalence is 
due to the fact that the age group with the 
highest rate of HBV infection 10 years ago, 
the then 70–79 year olds, did not partic-
ipate in the current survey for age-relat-
ed reasons. On the other hand there is 
also a lower rate of infection among the 
younger age groups. This can be attribut-
ed to the introduction of the general vac-
cination against hepatitis B for infants. In 
the age groups investigated here, however, 
the declining rate of infection is primari-
ly the result of vaccination of older chil-
dren and adolescents. Since all study par-
ticipants were born before the recommen-
dation for general vaccination was made, 
and as the vaccination coverage is higher 
in younger than in older age groups, it is 
likely that the positive trend will continue.
Hepatitis C
Hepatitis C is a contagious inflammation 
of the liver affecting people worldwide 
that is caused by the hepatitis C virus. 
HCV is transmitted parenterally. Without 
treatment the infection becomes chronic 
in 50–85% of cases [22, 23] and after de-
cades can result in cirrhosis of the liver 
or hepatocellular carcinoma. There is no 
vaccine against hepatitis C. The available 
diagnostic markers at present do not al-
low any assessment of the duration of in-
fection, so that in general it is not possible 
to differentiate between acute and chron-
ic infections. In comparison to the find-
ings from GNHIES98, the overall preva-
lence of hepatitis C in Germany remains 
unchanged. However, no hepatitis C pos-
itive results were found in the younger age 
groups 18–39 years in the current survey. 
Important preventative measures, includ-
ing routine hepatitis C screening as part of 
blood donor monitoring, were introduced 
in 1991. This may explain the decrease in 
HCV infection among the younger pop-
ulation. A further reduction in the num-
ber of chronic HCV infections can be ex-
pected as antiviral treatment options im-
prove [24].
Conclusion
With a prevalence of HCV infection of 
0.3%, Germany ranks among European 
nations as one of the countries with a low 
prevalence of hepatitis C [25]. The true 
prevalence of HCV antibodies may, how-
ever, be greater than indicated by DEGS1, 
since hospitalised patients, persons in psy-
chiatric care and prison-inmates were ex-
cluded from the survey and other risk 
groups such as intravenous drug users 
and other populations at higher risk of 





General-Pape-Str. 62–66, 12101 Berlin
Germany
poethko-muellerc@rki.de
Funding of the study. The study was financed by 
the Robert Koch Institute and the Federal Ministry of 
Health.
Conflict of interest. On behalf of all authors, the cor-
responding author states that there are no conflicts 
of interest.
References
 1. Gößwald A, Lange M, Kamtsiuris P, Kurth BM 
(2012) DEGS: German health interview and exam-
ination survey for adults. A nationwide cross-sec-
tional and longitudinal study within the frame-
work of health monitoring conducted by the Ro-
bert Koch-Institute. Bundesgesundheitsbl Gesund-
heitsforsch Gesundheitsschutz 55:775–780
 2. Kamtsiuris P, Lange M, Hoffmann R et al (2013) The 
first wave of the German health interview, and ex-
amination survey for adults (DEGS1). Sampling de-
sign, response, sample weights and representa-
tiveness. Bundesgesundheitsbl Gesundheitsforsch 
Gesundheitsschutz 56:620–630
 3. Kurth BM (2012) Das RKI-Gesundheitsmonitoring 
– was es enthält und wie es genutzt werden kann. 
Public Health Forum 20(76):4.e1–4.e3
 4. Kurth BM, Lange C, Kamtsiuris P, Hölling H (2009) 
Health Monitoring at the Robert Koch-Institute. 
Status and perspectives. Bundesgesundheitsbl Ge-
sundheitsforsch Gesundheitsschutz 52:557–570
 5. Scheidt-Nave C, Kamtsiuris P, Gößwald A et al 
(2012) Study protocol. German health interview 
and examination survey for adults (DEGS)—de-
sign, objectives and implementation of the first 
data collection wave (DEGS1). BMC Public Health 
12:730
 6. Gößwald A, Lange M, Dölle R, Hölling H (2013) The 
first wave of the German Health Interview and Ex-
amination Survey for Adults (DEGS1).Participant 
recruitment, fieldwork, and quality management.  
Bundesgesundheitsbl Gesundheitsforsch Gesund-
heitsschutz 56:611–619
 7. Robert Koch-Institut (Ed) (2009) DEGS: Studie 
zur Gesundheit Erwachsener in Deutschland—
Projekt beschreibung. Beiträge zur Gesundheits-
berichterstattung des Bundes. RKI, Berlin
 8. Lampert T, Kroll L, Müters S, Stolzenberg H (2013) 
Measurement of socioeconomic status in the Ger-
man health interview and examination survey for 
adults (DEGSS1). Bundesgesundheitsbl Gesund-
heitsforsch Gesundheitsschutz 56:631–636
 9. Gandhi RT, Wurcel A, Lee H et al (2005) Response 
to hepatitis B vaccine in HIV-1-positive subjects 
who test positive for isolated antibody to hepatitis 
B core antigen: implications for hepatitis B vaccine 
strategies. J Infect Dis 191:1435–1441
10. Ständige Impfkommission (1994) Impfempfehlun-
gen der Ständigen Impfkommission (STIKO) des 
Bundesgesundheitsamtes—Stand: September 
1993. Bundesgesundheitsblatt 2:85–91
11. Poethko-Müller C, Schmitz R (2013) Vaccination 
coverage in German adults. Results of the Ger-
man health interview and examination survey for 
adults (DEGS1). Bundesgesundheitsbl Gesund-
heitsforsch Gesundheitsschutz 56:845–858
12. Thierfelder W, Hellenbrand W, Meisel H et al (2001) 
Prevalence of markers for hepatitis A, B and C in 
the German population. Results of the German na-
tional health interview and examination survey 
1998. Eur J Epidemiol 17:429–435
13. Robert Koch-Institut (ed) (2012) Infektionsepide-
miologisches Jahrbuch für 2011. RKI, Berlin
14. Verhoef L, Boot HJ, Koopmans M et al (2011) 
Changing risk profile of hepatitis A in The Neth-
erlands: a comparison of seroprevalence in 
1995–1996 and 2006–2007. Epidemiolo Infect 
139:1172–1180
15. Van Herck K, Van Damme P, Lievens M, Stoffel M 
(2004) Hepatitis A vaccine: indirect evidence of im-
mune memory 12 years after the primary course. J 
Med Virol 72:194–196
16. Jacobsen KH, Koopman JS (2004) Declining hepa-
titis A seroprevalence: a global review and analy-
sis. Epidemiol Infect 132:1005–1022
17. Nothdurft HD (2008) Hepatitis A vaccines. Expert 
review of vaccines 7:535–545
18. Ständige Impfkommission (1996) Impfempfehlun-
gen der Ständigen Impfkommission (STIKO) des 
Bundesgesundheitsamtes—Stand: Oktober 1995. 
Bundesgesundheitsblatt 1:32–41
19. Robert Koch-Institut (2011) Zur Situation bei wich-
tigen Infektionskrankheiten in Deutschland – Vi-
rushepatitis B, C und D im Jahr 2010. Epidemiolo-
gisches Bulletin 29:261–271
20. Romano L, Paladini S, Van Damme P, Zanetti AR 
(2011) The worldwide impact of vaccination on 
the control and protection of viral hepatitis B. Dig 
Liver Dis 43:S2–S7
21. Robert Koch-Institut (2012) Impfquoten bei der 
Schuleingangsuntersuchung in Deutschland 2010. 
Epidemiol Bull 16:135–139
22. Seeff LB (2002) Natural history of chronic hepatitis 
C. Hepatology 36(5 Suppl 1):S35–S46
23. Seeff LB (2009) The history of the “natural history” 
of hepatitis C (1968–2009). Liv Int 29:89–93
24. Sarrazin C, Berg T, Cornberg M et al (2012) Ex-
pertenempfehlungen zur Triple-Therapie der HCV-
Infektion mit Boceprevir und Telaprevir. Z Gas-
troentrol 50:57–72
25. Rantala M, Laar MJ van de (2008) Surveillance and 
epidemiology of hepatitis B and C in Europe—a 
review. Euro Surveill 13:18880
8
Main topic
|  Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 5/6 · 2013
